S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan

GreenVision Acquisition (GRNV) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

GRNV vs. STAB, GMVDF, HGEN, HTGMQ, VRAYQ, AHPI, CALA, SCPS, GNCAQ, and GNCA

Should you be buying GreenVision Acquisition stock or one of its competitors? The main competitors of GreenVision Acquisition include Statera Biopharma (STAB), G Medical Innovations (GMVDF), Humanigen (HGEN), HTG Molecular Diagnostics (HTGMQ), ViewRay (VRAYQ), Allied Healthcare Products (AHPI), Calithera Biosciences (CALA), Scopus BioPharma (SCPS), Genocea Biosciences (GNCAQ), and Genocea Biosciences (GNCA). These companies are all part of the "medical" sector.

GreenVision Acquisition vs.

GreenVision Acquisition (NASDAQ:GRNV) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.

GreenVision Acquisition has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Comparatively, Statera Biopharma has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500.

GreenVision Acquisition has higher earnings, but lower revenue than Statera Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GreenVision AcquisitionN/AN/A-$510KN/AN/A
Statera Biopharma$1.49M0.02-$101.85MN/AN/A

GreenVision Acquisition received 1 more outperform votes than Statera Biopharma when rated by MarketBeat users.

CompanyUnderperformOutperform
GreenVision AcquisitionOutperform Votes
1
100.00%
Underperform Votes
No Votes
Statera BiopharmaN/AN/A

In the previous week, Statera Biopharma had 1 more articles in the media than GreenVision Acquisition. MarketBeat recorded 1 mentions for Statera Biopharma and 0 mentions for GreenVision Acquisition. GreenVision Acquisition's average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
GreenVision Acquisition Neutral
Statera Biopharma Neutral

Statera Biopharma's return on equity of 0.00% beat GreenVision Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
GreenVision AcquisitionN/A -54.82% -2.65%
Statera Biopharma N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GreenVision Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Statera Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Statera Biopharma beats GreenVision Acquisition on 5 of the 7 factors compared between the two stocks.


Get GreenVision Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRNV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRNV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

GRNV vs. The Competition

MetricGreenVision AcquisitionBusiness Services IndustryMedical SectorNASDAQ Exchange
Market Cap$37,000.00$1.84B$5.22B$7.62B
Dividend YieldN/A9.00%2.82%3.87%
P/E RatioN/A558.23255.8018.81
Price / SalesN/A91.373,089.98110.59
Price / CashN/A22.7599.8855.35
Price / BookN/A2.204.534.54
Net Income-$510,000.00-$6.06M$114.85M$211.55M

GreenVision Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STAB
Statera Biopharma
0 of 5 stars
$0.00
flat
N/A-97.8%$33,000.00$1.49M0.0046Gap Down
GMVDF
G Medical Innovations
0 of 5 stars
$0.01
+3.2%
N/AN/A$26,000.00$4.42M0.0084Gap Up
HGEN
Humanigen
0 of 5 stars
N/A$0.50
+∞
N/A$24,000.00$1.70M0.006News Coverage
HTGMQ
HTG Molecular Diagnostics
0 of 5 stars
$0.01
flat
N/AN/A$18,000.00$6.37M0.0053Gap Down
High Trading Volume
VRAYQ
ViewRay
0 of 5 stars
N/AN/AN/A$18,000.00$102.21M0.00295
AHPI
Allied Healthcare Products
0 of 5 stars
N/AN/AN/A$16,000.00$27.05M0.00189Analyst Report
News Coverage
CALA
Calithera Biosciences
0 of 5 stars
$0.03
flat
N/A-60.0%$146,000.00$9.75M0.008
SCPS
Scopus BioPharma
0 of 5 stars
$0.00
flat
N/A-97.0%$151,000.00N/A0.0013
GNCAQ
Genocea Biosciences
0 of 5 stars
N/AN/AN/A$10,000.00$1.64M0.0074
GNCA
Genocea Biosciences
0 of 5 stars
N/AN/AN/A$6,000.00$1.91M0.0074Analyst Report

Related Companies and Tools

This page (NASDAQ:GRNV) was last updated on 3/3/2024 by MarketBeat.com Staff